COVID-19 hit the SCS market hard in Q220 as shutdowns and widespread procedure cancellations led to a dramatic decline in SCS revenues.
COVID-19 clobbered the SCS market in Q220 as shutdowns and widespread procedure cancellations led to a dramatic decline in SCS revenues, with the biggest impact in April across all geographies. For Q220, WW SCS revenues tumbled down -38.1% vs Q219, and US SCS revenue dropped by -37.7% YoY according to SmartTRAK Financial Dashboard.
Among the many topics covered in the comprehensive Q220 SCS Market Recap* are:
- Complete Q220 Spinal Cord Stimulation Market Overview
- Medtronic: Making Inroads with DTM SCS
- Boston Scientific: Seeing Solid Recovery
- Abbott: Connectivity as a Competitive Edge
- Latest Innovation
- Nevro Capturing Share
- Omnia Gaining Traction
- PDN/NSRBP Update
- Selected Regulatory News
Read the entire Q220 SCS Market Recap including news, data, charts, company revenues and analysis*
*The entire article and the links can only be viewed by SmartTRAK subscribers to this module. For more information on how to receive a demo and subscribe, please click the button below.
